Nombre del producto:(4-Ethoxycarbonylphenyl)boronic acid

IUPAC Name:[4-(ethoxycarbonyl)phenyl]boronic acid

CAS:4334-88-7
Fórmula molecular:C9H11BO4
Pureza:97%
Número de catálogo:CM135619
Peso molecular:193.99

Unidad de embalaje Stock disponible Precio($) Cantidad
CM135619-100g in stock ƿƿȃ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :4334-88-7
Fórmula molecular:C9H11BO4
Punto de fusión:-
Código de sonrisas:C1=C(C(OCC)=O)C=CC(=C1)B(O)O
Densidad:
Número de catálogo:CM135619
Peso molecular:193.99
Punto de ebullición:
Nº Mdl:MFCD02179441
Almacenamiento:

Category Infos

Boronic Acids and Esters
Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).
Boronic Acid For Sale
Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.

Column Infos

Momelotinib
GSK’s novel small molecule drug, Momelotinib (Ojjaara) has been approved by the U.S. FDA on September 15 for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia.
Myelofibrosis is a rare and fatal form of bone marrow cancer, often resulting in anemia, constitutional symptoms such as fatigue, night sweats, and bone pain, and splenomegaly. These key manifestations of myelofibrosis, including anaemia, have limited treatment options and causing over 30% patients discontinuing treatment.
Momelotinib fills a significant unmet medical need, and has a potential of being a standard-of-care treatment for newly diagnosed and previously treated patients with anaemia. Under a unique mechanism of action, Momelotinib, inhibits Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1) along three key signalling pathways. The phase III study has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly.